Market Overview In 2022, the global market size for drug-eluting stents reached USD 7.21 Billion and is projected to attain USD 12.18 Billion by 2032, exhibiting a revenue Compound Annual Growth Rate (CAGR) of 6% throughout the forecast period. The driving forces behind this growth include the increasing prevalence of cardiovascular disorders, such as coronary artery disease and peripheral artery disease, coupled with a growing preference for minimally invasive procedures.
Factors Driving Growth A significant contributor to the market's revenue growth is the escalating incidence of cardiovascular diseases, responsible for approximately 18 million annual fatalities globally, according to the World Health Organization. The aging population and sedentary lifestyle further elevate the risk of cardiovascular diseases, boosting the demand for drug-eluting stents.
Get a sample copy of the Drug Eluting Stent Market report: https://www.reportsanddata.com/download-free-sample/1786
The inclination towards minimally invasive procedures, characterized by shorter recovery periods, reduced expenses, and shorter hospital stays, is another key factor propelling market growth. Additionally, advancements in drug-eluting stent technology, including the development of biodegradable stents, contribute to the expansion of the market.
Challenges and Restraints Despite the positive trajectory, the high cost of drug-eluting stent treatment poses a significant challenge to market growth, especially when compared to bare metal stent therapy. Stringent regulatory approval processes, particularly by bodies like the U.S. Food and Drug Administration (FDA), requiring comprehensive clinical data, also hinder the market's progress.
Emerging Market Trends
Recent developments in the market include the introduction of bioresorbable stents designed to gradually disintegrate, thereby reducing the risk of in-stent restenosis and improving long-term patient outcomes. Drug-Eluting Balloons (DEBs) are gaining popularity as viable alternatives to drug-eluting stents, mitigating the potential for long-term complications associated with the permanent implantation of stents.
Government Regulations
Various regulatory authorities worldwide oversee the approval and utilization of drug-eluting stents. Examples include the FDA in the United States, the European Union's Medical Device Regulation, and guidelines from the World Health Organization, all emphasizing the importance of safe and effective usage. Comparable regulatory oversight is present in Australia and China, with the Therapeutic Goods Administration and the State Food and Drug Administration, respectively.
Product Overview
The global market categorizes drug-eluting stents into polymer-based, biodegradable, and other segments. Polymer-based stents dominated the market in 2021, attributed to their effectiveness in preventing restenosis and reducing the need for additional treatments. Biodegradable stents are anticipated to demonstrate the highest revenue Compound Annual Growth Rate (CAGR), offering sustained drug delivery while minimizing long-term risks.
Application Landscape In terms of application, the market is segmented into coronary artery disease and peripheral artery disease. Coronary artery disease accounted for a substantial revenue share in 2021, driven by its high prevalence globally. However, the segment for peripheral artery disease is projected to experience the fastest revenue CAGR, attributed to the increasing prevalence of the disease and technological advancements in tailored drug-eluting stent solutions.
Regional Insights The Asia-Pacific region is anticipated to dominate the drug-eluting stent market, driven by the rise in cardiovascular ailments, aging populations, and sedentary lifestyles. North America is expected to witness significant growth, with the United States playing a pivotal role due to its established healthcare infrastructure and adoption of advanced technologies. Europe and the Middle East & Africa are also forecasted to contribute steadily to market expansion.
Competitive Landscape The global drug eluting stent market is highly competitive, with major players adopting strategies such as mergers, acquisitions, partnerships, and collaborations to enhance market positions. Key companies in the market include Abbott Laboratories, Boston Scientific Corporation, Medtronic, Cordis Corporation (a Johnson & Johnson company), Terumo Corporation, Biosensors International Group, Ltd., Biotronik SE & Co. KG, and St. Jude Medical, Inc.
Strategic Developments Major companies continue to focus on strategic developments to strengthen their market presence. For instance, Abbott Laboratories received FDA approval for its XIENCE Skypoint Everolimus-Eluting Coronary Stent System, while Boston Scientific Corporation acquired Preventice Solutions for $1.2 billion to bolster its digital health offerings and competitive edge in the drug-eluting stent market.
New Product Launches In response to market demands, key players have introduced new products, such as Abbott Laboratories' XIENCE Skypoint Everolimus-Eluting Coronary Stent System, Boston Scientific Corporation's SYNERGY Megatron Everolimus-Eluting Platinum Chromium Coronary Stent System, and Medtronic's Resolute Onyx drug-eluting stent system. These innovations aim to provide improved clinical outcomes and ease of use for physicians.
Explore Trending Reports:
Tetrahydrofuran (THF) Market -https://bhagyashrishewale.blogspot.com/2023/06/tetrahydrofuran-thf-marke...
Benzoic Acid Market -https://bhagyashrishewale.blogspot.com/2023/06/benzoic-acid-market-is-ex...
Acrylic Monomers Market -https://bhagyashrishewale.blogspot.com/2023/06/acrylic-monomers-market-t...
Bitumen Membranes Market -https://bhagyashrishewale.blogspot.com/2023/06/bitumen-membranes-market-...
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/1786
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release